Pharmaceutical Stock Flies Higher on Drug Announcement

the only analyst in coverage carries a "buy" rating

Deputy Editor
Jun 19, 2020 at 11:28 AM
facebook twitter linkedin

The shares of Australian biopharmaceutical company Immuron Limited (NASDAQ:IMRN) are up 40.8% at $10.91 at last check, after announcing plans to create a diarrhea drug for evaluation by the U.S. Defense Department. The drug will be produced by CSIRO using vaccines developed by the U.S. Naval Medical Research Center, and the Naval Medical research center plans to submit a pre-investigational new drug (IND) information package to the U.S. Food and Drug Administration (FDA). 

IMRN has fallen far below its recent all-time high of $28.99 on June 9. Now a chip-shot away from its support at the 10-day moving average, the equity is climbing on the charts once again, up a whopping 504% in the last three months alone. It's also worth noting that trading was halted today due to the stock's massive swing in volatility. 

The lone analyst in coverage carries a "buy" rating. Meanwhile, the 12-month consensus price target of $6 is a 44.7% discount to current levels. 




Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners